Skip to main content

RheumNow Podcast – with Special Guest Dr. Janet Pope (9.8.2023)

Sep 08, 2023 6:00 am

This week, Dr. Jack Cush reviews the news with special guest, Dr. Janet Pope. They discuss "Not-non-Inferior", large scale genetic screening, Zoster risk w/ newer lupus drugs, tapering, RA referral problems and the TNR webinar session on "ORAL Surveillance Revisited".

  1. Placebo is not non-inferior to colchicine in gout flare prevention in 1st 6 mos of allopurinol. 12 mos 200 pts allopurinol, 6 mos of COL 0.5 mg qd; Gout flares - 0.61 PBO vs 0.35 Colchicine. After stopping colchicine, no difference in gout flares/month between groups over 12-mos
  2. Genomic sequencing of 29601 newborns found 2.7% (813) w/ genetic dz - half were ultimately dx, PPV=50.4%. About 1 out of every 500 newborns will benefit from the implementation of gene panels as a first-tier screening test in newborns.
  3. Anifrolumab targets type I IFN pathway. In #SLE Trials, pts on ANIF had as much as 8-fold higher rate of Herpes zoster. HZ incidence is 6.9 vs 1.5/100 PYs on ANIF vs PBO. Other drugs may affect IFN - sifalimumab litifilimab, daxdilimab, deucravacitinib
  4. 84 #RA pts in remission >1 yr on TNFi showed an increase in flare rate if TNFi tapered to D/C ( 63% TNFi taper group vs 5%) in stable TNFi group). Tapering strategy was not non-inferior to continued Tx; Most regained remission after TNFi reinstatement
  5. Woeful Rheumatology Referrals 
  6. ACR ILD Guidelines 
  7. Oral Surveillance Changes in Advanced Therapy Use in RA
  8. Oral Surveillance Revisited


If you are a health practitioner, you may to comment.

Due to the nature of these comment forums, only health practitioners are allowed to comment at this time.

The author has received compensation as an advisor or consultant on this subject